Cargando…
Lurbinectedin: an FDA-approved inducer of immunogenic cell death for the treatment of small-cell lung cancer
Lurbinectedin is a DNA-binding inhibitor of transcription that potently induces immunogenic cell death (ICD). In June 2020, the Federal Drug Administration (FDA) approved lurbinectedin for the salvage treatment of small-cell lung cancer that has relapsed from platinum compound-based first-line chemo...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Taylor & Francis
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458590/ https://www.ncbi.nlm.nih.gov/pubmed/32923159 http://dx.doi.org/10.1080/2162402X.2020.1795995 |